|Bid||159.63 x 800|
|Ask||166.19 x 800|
|Day's Range||157.09 - 161.60|
|52 Week Range||108.85 - 177.99|
|Beta (5Y Monthly)||0.50|
|PE Ratio (TTM)||45.65|
|Earnings Date||Jul. 23, 2020 - Jul. 27, 2020|
|Forward Dividend & Yield||1.56 (0.98%)|
|Ex-Dividend Date||May 13, 2020|
|1y Target Est||166.80|
ResMed (RMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ResMed and Rugby League Hall of Famer and head coach Brad Fittler are teaming up to raise Australians' awareness of the importance of healthy sleep.
Propeller Health's digital sensor and app for AstraZeneca's Symbicort inhaler has received 510(k) clearance from the U.S. FDA.
Over 140 long-term care facility and home-based care employees recognized for commitment to patient and resident safety during the COVID-19 pandemic.
Based on a brief questionnaire remotely filled by the patient, the MaskSelector tool recommends the best suitable ResMed (RMD) mask for patients.
Investors continue to be optimistic about ResMed (RMD) on its focus on digital health technology and robust demand for its critical care products.
ResMed MaskSelector is here, a digital tool to make remote patient CPAP mask selection and sizing easier and more effective.
ResMed cleared 166.05 cup-with-handle buy point. The company makes sleep apnea products. Some of its products may help coronavirus patients. RMD reported 45% earnings growth on April 30, fourth straight quarter of acceleration.
ResMed President and COO Rob Douglas will participate in a virtual fireside chat at the Bank of America Securities Healthcare Conference 2020.
ResMed’s AirView platform helps clinicians remotely monitor and advise ventilator and bilevel device patients safer by reducing in-person visits.
Joining me on the call today to discuss our quarterly results from various remote locations across San Diego and Sydney are CEO, Mick Farrell; and CFO, Brett Sandercock; as well as other members of management who will be available during the Q&A portion of our call. Thanks, Amy, and thank you all for joining us today.
The medical product companies have partially mitigated the impact of the pandemic driven by the massive adoption of COVID-19 related healthcare-support products and services.
Zacks.com featured highlights include: Keysight Technologies, ResMed, Cigna and Jack Henry & Associates
Growth at a reasonable price or GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount.
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ResMed (RMD) is expected to have gained from increased adoption of flagship products and a ramped-up ventilator production capacity in Q3 amid the coronavirus pandemic.
The Senate approved a new $484 billion stimulus bill on Tuesday, marking another phase of government support and leaving many wondering how the money will be dispersed. Yahoo Finance’s Anjalee Khemlani joins The Final Round panel to break down the latest news about the coronavirus.